市場調査レポート
商品コード
1271995

コンパニオン診断 (CDx):各種技術と市場

Companion Diagnostics: Technologies and Markets

出版日: | 発行: BCC Research | ページ情報: 英文 286 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
コンパニオン診断 (CDx):各種技術と市場
出版日: 2023年05月05日
発行: BCC Research
ページ情報: 英文 286 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のコンパニオン診断 (CDx) の市場規模は、2022年の64億米ドルから、2022年から2027年にかけて15.3%のCAGRで推移し、2027年には130億米ドルの規模に成長すると予測されています。

消耗品の部門は、2022年の36億米ドルから、15.8%のCAGRで推移し、2027年には75億米ドルの規模に成長すると予測されています。

また、サービスの部門は、2022年の13億米ドル米ドルから、15.6%のCAGRで推移し、2027年には27億米ドルの規模に成長すると予測されています。

当レポートでは、世界のコンパニオン診断 (CDx) の市場を調査し、市場および技術の背景、市場規模の推移・予測、各種区分・地域別の詳細分析、特許動向、市場影響因子の分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリーおよびハイライト

第3章 市場および技術の背景

  • 個別化医療とバイオマーカー
  • コンパニオン診断と補完診断

第4章 世界のコンパニオン診断 (CDx) 市場:製品・サービス別

  • 市場概要
  • 市場シェア・予測
    • 機器
    • 消耗品
    • サービス

第5章 世界のコンパニオン診断 (CDx) 市場:検査タイプ別

  • 市場概要
  • 市場シェア・予測
    • LDT-CDx
    • 商用CDx

第6章 世界のコンパニオン診断 (CDx) 市場:技術別

  • 市場概要
  • 市場シェア・予測
    • 免疫組織化学
    • In situハイブリダイゼーション
    • ポリメラーゼ連鎖反応
    • 次世代シーケンシング
    • ジェノタイピング
    • その他
    • サービス

第7章 世界のコンパニオン診断 (CDx) 市場:用途別

  • 市場概要
  • 市場シェア・予測
    • 神経疾患
    • 循環器疾患
    • 感染症
    • その他

第8章 世界のコンパニオン診断 (CDx) 市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第9章 産業構造

  • 概要
  • ステークホルダー
  • 推進動向
  • ビジネスモデル
  • 助成金・資金提供
  • コラボレーション・パートナーシップ
  • M&A
  • 主要企業:技術別
    • IHC
    • ISH
    • PCR
    • NGS
    • ジェノタイピング
    • その他

第10章 特許レビュー

第11章 臨床試験分析

  • 臨床試験とCDx
  • 臨床試験分析

第12章 市場機会の分析

  • 市場力学
    • 強み
    • 課題
    • 機会
    • 脅威
  • COVID-19の影響

第13章 企業プロファイル

  • ABBOTT
  • ADAPTIVE BIOTECHNOLOGIES CORP.
  • AGILENT TECHNOLOGIES INC.
  • AMOY DIAGNOSTICS CO., LTD.
  • ALMAC GROUP LTD.
  • ARUP LABORATORIES
  • AUTOGENOMICS INC.
  • BIOCARTIS
  • BIODESIX INC.
  • BIOFLUIDICA
  • BIOMERIEUX SA
  • BIO-TECHNE
  • CERBA RESEARCH
  • CIRCULOGENE
  • DANAHER
  • DIASORIN S.P.A.
  • EXACT SCIENCES CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • GUARDANT HEALTH INC.
  • HOLOGIC INC.
  • ICON PLC
  • ILLUMINA INC.
  • INVIVOSCRIBE INC.
  • MAZE THERAPEUTICS
  • MYRIAD GENETICS INC.
  • NEOGENOMICS LABORATORIES
  • QIAGEN
  • QUEST DIAGNOSTICS INC.
  • RESONANCE HEALTH LTD.
  • SIEMENS HEALTHINEERS AG
  • SPARTAN BIOSCIENCE INC.
  • SYSMEX CORP.
  • THERMO FISHER SCIENTIFIC INC.
  • TRIMGEN CORP.
  • VELA DIAGNOSTICS INC.

第14章 付録:頭字語

図表

List of Tables

  • Summary Table A : Global Market for Companion Diagnostics, by Product and Service, Through 2027
  • Summary Table B : Global Market for Companion Diagnostics, by Region, Through 2027
  • Table 1 : Examples of Predictive Biomarkers
  • Table 2 : Biomarkers Used in Companion Diagnostics
  • Table 3 : Commercial CDx vs. LDT-CDx
  • Table 4 : Examples of Technologies Used in Different CDx
  • Table 5 : FDA List of Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations
  • Table 6 : Different Agents Used for Chemotherapy and Targeted Therapy
  • Table 7 : Comparison Between Chemotherapy and Targeted Therapy
  • Table 8 : Differences Among PMA, HDE and 510(k) Applications for CDx
  • Table 9 : CLIA Categorization Criteria
  • Table 10 : Regulatory Approvals Granted for CDx
  • Table 11 : Global Market for Companion Diagnostics, by Product and Service, Through 2027
  • Table 12 : Companion Diagnostics Instruments
  • Table 13 : Global Market for Companion Diagnostics Instruments, by Region, Through 2027
  • Table 14 : Global Market for Companion Diagnostics Consumables, by Region, Through 2027
  • Table 15 : Global Market for Companion Diagnostics Services, by Region, Through 2027
  • Table 16 : Global Market for Companion Diagnostics, by Type of Test, Through 2027
  • Table 17 : Laboratory Developed Test (LDT) Assays Approved by the FDA as a Companion Diagnostics (CDx)
  • Table 18 : Global Market for Laboratory Developed Test (LDT)-CDx, by Region, Through 2027
  • Table 19 : FDA Approved Companion Diagnostics, March 2023
  • Table 20 : Global Market for Commercial-CDx, by Region, Through 2027
  • Table 21 : FDA-Approved CDx Technologies, by Year, 2000-June 2021
  • Table 22 : Number and Percentage of FDA-Approved CDx Tests, by Technology, 2000-June 2021
  • Table 23 : Global Market for Companion Diagnostics, by Technology, Through 2027
  • Table 24 : FDA-Approved IHC-CDx
  • Table 25 : Global Market for Immunohistochemistry CDx, by Region, Through 2027
  • Table 26 : FDA-Approved ISH-CDx
  • Table 27 : Global Market for In Situ Hybridization CDx, by Region, Through 2027
  • Table 28 : FDA-Approved PCR-CDx
  • Table 29 : Global Market for Polymerase Chain Reaction CDx, by Region, Through 2027
  • Table 30 : FDA-Approved NGS-CDx
  • Table 31 : Foundation Medicine CDx: Indications and Biomarkers
  • Table 32 : Global Market for Next-Generation Sequencing CDx, by Region, Through 2027
  • Table 33 : FDA-Cleared Pharmacogenetic Tests
  • Table 34 : Global Market for Genotyping CDx, by Region, Through 2027
  • Table 35 : Global Market for Other CDx Technologies, by Region, Through 2026
  • Table 36 : Technological Expertise in CDx Services Sector
  • Table 37 : Global Market for CDx Services, by Region, Through 2027
  • Table 38 : Global Market for Companion Diagnostics, by Application, Through 2027
  • Table 39 : Drugs with Approved Companion Diagnostics
  • Table 40 : Global Market for Companion Diagnostics in Cancer Applications, by Region, Through 2027
  • Table 41 : Cancer Incidence, Global, by Cancer Type, 2020
  • Table 42 : Total Number of Drugs with Approved CDx, by Cancer Type, 2021
  • Table 43 : Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, Through 2027
  • Table 44 : Global Market for Companion Diagnostics in Neurologic Disorders Applications, by Region, Through 2027
  • Table 45 : Estimated Deaths Due to Cardiovascular Disease, by Gender and Disease, 2019
  • Table 46 : Global Market for Companion Diagnostics in Cardiovascular Disease Application, by Region, Through 2027
  • Table 47 : Classes of ART
  • Table 48 : Global Market for Companion Diagnostics in Infectious Disease Application, by Region, Through 2027
  • Table 49 : Global Market for Companion Diagnostics in Other Disease Applications, by Region, Through 2027
  • Table 50 : Global Market for Companion Diagnostics, by Region, Through 2027
  • Table 51 : North American Market for Companion Diagnostics, by Country, Through 2027
  • Table 52 : U.S. Estimated Number of New Cancer Cases, by Cancer Site, 2021
  • Table 53 : European Market for Companion Diagnostics, by Country, Through 2027
  • Table 54 : Asia-Pacific Market for Companion Diagnostics, by Country, Through 2027
  • Table 55 : Grants and Funding in Companion Diagnostics, 2019-July 15, 2020
  • Table 56 : Collaborations and Partnerships in the Global Companion Diagnostics Market, 2019-February 2023
  • Table 57 : Mergers and Acquisitions in the Global Companion Diagnostics Market, 2019-2020
  • Table 58 : Companion Diagnostics: Market Share Analysis
  • Table 59 : IHC Companion Diagnostics, Product
  • Table 60 : Leading Market Players of IHC Companion Diagnostics, 2021
  • Table 61 : ISH Companion Diagnostics, Product
  • Table 62 : Leading Market Players of ISH Companion Diagnostics, 2021
  • Table 63 : PCR Companion Diagnostics, Product
  • Table 64 : Leading Market Players of PCR Companion Diagnostics, 2021
  • Table 65 : NGS Companion Diagnostics, Products
  • Table 66 : Leading Market Players of NGS Companion Diagnostics, 2021
  • Table 67 : Genotyping Companion Diagnostics, Products
  • Table 68 : Leading Market Players of Genotyping Companion Diagnostics, 2021
  • Table 69 : Other Companion Diagnostics, Products
  • Table 70 : Leading Market Players of Other Companion Diagnostics, 2021
  • Table 71 : Basic Aspects of Patents
  • Table 72 : Representative Patents on Companion Diagnostics, 2018-June 2021
  • Table 73 : Number of Patents Issued on Companion Diagnostics, by Top Applicant, 2018-2022
  • Table 74 : Number of Patents Issued on Companion Diagnostics, by Top Owner, 2018-2022
  • Table 75 : Number of Patents Issued on Companion Diagnostics, by Jurisdiction, 2017-2022
  • Table 76 : Clinical Trials on Companion Diagnostics, by Type of Study, March 2023
  • Table 77 : Clinical Trials on Companion Diagnostics, by Status, March 2023
  • Table 78 : Clinical Trials on Companion Diagnostics, by Phase, March 2023
  • Table 79 : Clinical Trials on Companion Diagnostics, by Region, March 2023
  • Table 80 : Clinical Trials on Companion Diagnostics, by Application, March 2023
  • Table 81 : Companies with CDx in Clinical Trials, March 2023
  • Table 82 : Companion Diagnostics and Approved Drugs, 2020-2022
  • Table 83 : FoundationOne CDx Approved Indications
  • Table 84 : Common Inefficiencies in Clinical Testing Landscape
  • Table 85 : Initiatives Towards Harmonization of Commercial and LDT-CDx
  • Table 86 : All of Us Research Program Highlights
  • Table 87 : Abbott: Product Portfolio
  • Table 88 : Agilent Technologies Inc.: Product Portfolio
  • Table 89 : Agilent Technologies Inc: Key Developments, 2021-2023
  • Table 90 : Amoy Diagnostics: Key Developments, 2020-2022
  • Table 91 : Biocartis: Key Developments, 2020-2023
  • Table 92 : Danaher Corp.: Key Developments, 2021-2022
  • Table 93 : F. Hoffmann-La Roche Ltd.: Key Developments, 2021-2023
  • Table 94 : Guardant Health Inc.: Key Developments, 2021-2022
  • Table 95 : Hologic Inc.: Key Developments, 2021
  • Table 96 : Illumina Inc.: Key Developments, 2021-2022
  • Table 97 : Invivoscribe: Key Developments, 2020-2022
  • Table 98 : Qiagen NV: Key Developments, 2021-2022
  • Table 99 : Thermo Fisher Scientific Inc.: List of Pipeline Companion Diagnostics
  • Table 100 : Thermo Fisher Scientific Inc.: Key Developments, 2021-2023
  • Table 101 : Acronyms Used in This Report

List of Figures

  • Summary Figure A : Global Market for Companion Diagnostics, by Product and Service, 2019-2027
  • Summary Figure B : Global Market for Companion Diagnostics, by Region, 2019-2027
  • Figure 1 : Companion Diagnostics Co-development Process from Biomarker Discovery to Regulatory Approval
  • Figure 2 : Overview of the Key Priorities/Needs for CDx Tests Across Stakeholders
  • Figure 3 : Global Market for Companion Diagnostics, by Product and Service, 2019-2027
  • Figure 4 : Global Market Shares of Companion Diagnostics, by Product and Service, 2021
  • Figure 5 : Global Market for Companion Diagnostics Instruments, by Region, 2019-2027
  • Figure 6 : Global Market for Companion Diagnostics Consumables, by Region, 2019-2027
  • Figure 7 : Global Market for Companion Diagnostics Services, by Region, 2019-2027
  • Figure 8 : Global Market for Companion Diagnostics, by Type of Test, 2019-2027
  • Figure 9 : Global Market Shares of Companion Diagnostics, by Type of Test, 2021
  • Figure 10 : Global Market for Laboratory Developed Test (LDT)-CDx, by Region, 2019-2027
  • Figure 11 : Global Market for Commercial-CDx, by Region, 2019-2027
  • Figure 12 : Share of FDA-Approved CDx Tests, by Technology, 2000-June 2021
  • Figure 13 : Global Market for Companion Diagnostics, by Technology, 2019-2027
  • Figure 14 : Global Market Shares of Companion Diagnostics, by Technology, 2021
  • Figure 15 : Global Market for Immunohistochemistry CDx, by Region, 2019-2027
  • Figure 16 : Global Market for In Situ Hybridization CDx, by Region, 2019-2027
  • Figure 17 : Global Market for Polymerase Chain Reaction CDx, by Region, 2019-2027
  • Figure 18 : Global Market for Next-Generation Sequencing CDx, by Region, 2019-2027
  • Figure 19 : Global Market for Genotyping CDx, by Region, 2019-2027
  • Figure 20 : Global Market for Other CDx Technologies, by Region, 2019-2027
  • Figure 21 : Global Market for CDx Services, by Region, 2019-2027
  • Figure 22 : Global Market for Companion Diagnostics, by Application, 2019-2027
  • Figure 23 : Global Market Shares of Companion Diagnostics, by Application, 2021
  • Figure 24 : Global Market for Companion Diagnostics in Cancer Applications, by Region, 2019-2027
  • Figure 25 : Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, 2019-2027
  • Figure 26 : Global Market Shares of Companion Diagnostics in Cancer Applications, by Cancer Type, 2021
  • Figure 27 : Global Market for Companion Diagnostics in Neurologic Disorders Applications, by Region, 2019-2027
  • Figure 28 : Global Market for Companion Diagnostics in Cardiovascular Disease Application, by Region, 2019-2027
  • Figure 29 : Global Market for Companion Diagnostics in Infectious Disease Application, by Region, 2019-2027
  • Figure 30 : Global Market for Companion Diagnostics in Other Disease Applications, by Region, 2019-2027
  • Figure 31 : Global Market for Companion Diagnostics, by Region, 2019-2027
  • Figure 32 : Global Market Shares of Companion Diagnostics, by Region, 2021
  • Figure 33 : North American Market for Companion Diagnostics, by Country, 2019-2027
  • Figure 34 : North American Market Shares of Companion Diagnostics, by Country, 2021
  • Figure 35 : U.S. Market for Companion Diagnostics, 2019-2027
  • Figure 36 : Canadian Market for Companion Diagnostics, 2019-2027
  • Figure 37 : European Market for Companion Diagnostics, by Country, 2019-2027
  • Figure 38 : European Market Shares of Companion Diagnostics, by Country, 2021
  • Figure 39 : German Market for Companion Diagnostics, 2019-2027
  • Figure 40 : U.K. Market for Companion Diagnostics, 2019-2027
  • Figure 41 : French Market for Companion Diagnostics, 2019-2027
  • Figure 42 : Cancer Incidence in Italy, by Cancer Type, 2020
  • Figure 43 : Italian Market for Companion Diagnostics, 2019-2027
  • Figure 44 : Rest of the European Market for Companion Diagnostics, 2019-2027
  • Figure 45 : Asia-Pacific Market for Companion Diagnostics, by Country, 2019-2027
  • Figure 46 : Asia-Pacific Market Shares of Companion Diagnostics, by Country, 2021
  • Figure 47 : Cancer Incidence in China, by Cancer Type,2020
  • Figure 48 : Distribution Share of Cancer Incidence in China, by Cancer Type, 2020
  • Figure 49 : Chinese Market for Companion Diagnostics, 2019-2027
  • Figure 50 : Japanese Market for Companion Diagnostics, 2019-2027
  • Figure 51 : Indian Market for Companion Diagnostics, 2019-2027
  • Figure 52 : Rest of Asia-Pacific Market for Companion Diagnostics, 2019-2027
  • Figure 53 : RoW Market for Companion Diagnostics, 2019-2027
  • Figure 54 : Perspective of Different Stakeholders in CDx Market
  • Figure 55 : Companion Diagnostics Business Models
  • Figure 56 : Number of Patents Issued on Companion Diagnostics, by Year, 2018-2022
  • Figure 57 : Number of Patents Issued on Companion Diagnostics, by Top Applicant, 2018-2022
  • Figure 58 : Number of Patents Issued on Companion Diagnostics, by Top Owner, 2018-2022
  • Figure 59 : Clinical Trials on Companion Diagnostics, by Type of Study, March 2023
  • Figure 60 : Clinical Trials on Companion Diagnostics, by Status, March 2023
  • Figure 61 : Clinical Trials on Companion Diagnostics, by Phase, March 2023
  • Figure 62 : SWOT Analysis of the Global Companion Diagnostics Market
  • Figure 63 : Distribution Share of Global Cancer Incidence, by Region, 2020
  • Figure 64 : Estimated Global Cancer Incidence, by Region, 2020 vs. 2040
  • Figure 65 : Number of Personalized Medicines in the Global Drug Market, 2008-2020
  • Figure 66 : Abbott: Diagnostics Annual Revenue, 2019-2021
  • Figure 67 : Abbott: Diagnostics Market Share, by Business Segment, 2021
  • Figure 68 : Abbott: Diagnostics Market Share, by Region, 2021
  • Figure 69 : Adaptive Biotechnologies Corp.: Total Revenue, 2019-2021
  • Figure 70 : Adaptive Biotechnologies Corp.: Market Share, by Business Segment, 2021
  • Figure 71 : Agilent Technologies Inc.: Diagnostics and Genomics Revenue, 2019-2021
  • Figure 72 : Agilent Technologies Inc.: Market Share, by Business Segment, 2021
  • Figure 73 : Agilent Technologies Inc.: Market Share, by Region, 2021
  • Figure 74 : Biocartis: Total Revenue, 2019-2021
  • Figure 75 : Biocartis: Market Share, by Business Segment, 2021
  • Figure 76 : Biocartis: Market Share, by Geography, 2021
  • Figure 77 : Biodesix Inc.: Total Revenue, 2019-2021
  • Figure 78 : Biodesix Inc.: Market Share, by Business Segment, 2021
  • Figure 79 : Biodesix Inc.: Market Share, by Region, 2021
  • Figure 80 : bioMerieux SA: Total Revenue, 2019-2021
  • Figure 81 : bioMerieux SA : Market Share, by Business Segment, 2021
  • Figure 82 : bioMerieux SA : Market Share, by Region, 2021
  • Figure 83 : Bio-Techne Corp.: Total Revenue, 2019-2021
  • Figure 84 : Bio-Techne Corp.: Market Share, by Business Segment, 2021
  • Figure 85 : Bio-Techne Corp.: Market Share, Diagnostics, by Geography, 2021
  • Figure 86 : Danaher Corp.: Annual Revenue, 2019-2021
  • Figure 87 : Danaher Corp.: Market Share, by Business Segment, 2021
  • Figure 88 : Danaher: Market Share, by Geography, 2021
  • Figure 89 : F. Hoffmann-La Roche Ltd.: Total Revenue, 2019-2021
  • Figure 90 : F. Hoffmann-La Roche Ltd.: Market Share, by Business Segment, 2021
  • Figure 91 : F. Hoffmann-La Roche Ltd.: Market Share, by Region, 2021
  • Figure 92 : Hologic Inc.: Annual Revenue, 2019-2021
  • Figure 93 : Hologic Inc.: Market Share, by Business Segment, 2021
  • Figure 94 : Hologic Inc.: Market Share, by Region, 2021
  • Figure 95 : Illumina Inc.: Annual Revenue, 2019-2021
  • Figure 96 : Illumina Inc.: Market Share, by Business Segment, 2021
  • Figure 97 : Illumina Inc.: Market Share, by Region, 2021
  • Figure 98 : Qiagen NV: Annual Revenue, 2019-2021
  • Figure 99 : Qiagen NV: Market Share, by Business Segment, 2021
  • Figure 100 : Qiagen NV: Market Share, by Region, 2021
  • Figure 101 : Siemens Healthineers AG: Annual Revenue, 2019-2021
  • Figure 102 : Siemens Healthineers AG: Market Share, by Business Segment, 2021
  • Figure 103 : Siemens Healthineers AG: Market Share, by Region, 2021
  • Figure 104 : Sysmex Corp.: Annual Revenue, 2019-2021
  • Figure 105 : Sysmex Corp.: Market Share, by Business Segment, 2021
  • Figure 106 : Sysmex Corp.: Market Share, by Region, 2021
  • Figure 107 : Thermo Fisher Scientific Inc.: Annual Revenue, 2019-2021
  • Figure 108 : Thermo Fisher Scientific Inc.: Market Share, by Region, 2021
  • Figure 109 : Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2021
目次
Product Code: BIO077E

Highlights:

The global market for companion diagnostics (CDx) is estimated to increase from $6.4 billion in 2022 to reach $13.0 billion by 2027, at a compound annual growth rate (CAGR) of 15.3% from 2022 through 2027.

The global market for companion diagnostics consumables is estimated to increase from $3.6 billion in 2022 to reach $7.5 billion by 2027, at a CAGR of 15.8% from 2022 through 2027.

The global market for companion diagnostics services is estimated to increase from $1.3 billion in 2022 to reach $2.7 billion by 2027, at a CAGR of 15.6% from 2022 through 2027.

Report Scope:

The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints and challenges in the market. The report also features market projections to 2027 and market ranking for key market players. It also covers the competitive environment and regulatory scenario. The report details the companion diagnostics market share based on product and Service, type of test, technology and application. The market is segmented based on product and Service into instruments, consumables and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, others, and services. Based on the application, the companion diagnostics market is segmented into cancer, neurologic disorders, cardiovascular disease, infectious disease and others. The report includes company profiles of the key players in the companion diagnostics market with detailed information about each company's business segments, financials, product portfolios and recent developments. The report also covers the impact of the COVID-19 pandemic on this market.

By geography, the market has been segregated into North America, Europe, Asia-Pacific and the Rest of the world. The North American region includes countries such as the U.S. and Canada; Europe includes Germany, U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 as the historic year, 2021 as the base year and 2027 as the forecast year.

Report Includes:

  • 43 data tables and 60 additional tables
  • Detailed overview and an up-to-date analysis of the global market for companion diagnostics (CDx)
  • Analyses of the global market trends, with historic market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Estimation of the actual market size and revenue forecast for the global CDx market in USD million values, and corresponding market share analysis by product and service, technology, application, type of test, and region
  • Identification of the viable technology drivers and barriers through a holistic review of various platform technologies and their potential applications in the development of new CDx products
  • Discussion of feasible market opportunities for companion diagnostics products via identification of high-growth applications in different therapeutic areas, with a focus on the biggest and fastest-expanding markets for diseases
  • Updated information on recent market developments and clinical trials, as well as the leading companies engaged in research and development (R&D) and products in the companion diagnostics reagent pipeline with SWOT analyses
  • Review of the patents and patent applications on companion diagnostics and deep dive of recent patent publications related to CDx products and technologies
  • Insight into the recent industry structure of companion diagnostics, competitive aspects of each product segments, increasing investment on R&D activities, market growth strategies, and company revenue share analysis
  • Descriptive company profiles of the leading global players, including Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Foundation Medicine Inc., Myriad Genetics Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction

  • 1.1 Overview
  • 1.2 Study Goals and Objectives
  • 1.3 Reasons for Doing This Study
  • 1.4 What's New in This Update?
  • 1.5 Scope of Report
  • 1.6 Information Sources
  • 1.7 Research Methodology
  • 1.8 Geographic Breakdown
  • 1.9 Analyst's Credentials
  • 1.10 BCC Custom Research
  • 1.11 Related BCC Research Reports

Chapter 2 Summary and Highlights

  • 2.1 Highlights of the Market for Companion Diagnostics (CDx)

Chapter 3 Market and Technology Background

  • 3.1 Introduction
  • 3.2 Personalized Medicine and Biomarkers
    • 3.2.1 Predictive Biomarkers
  • 3.3 Companion Diagnostics and Complementary Diagnostics
    • 3.3.1 Companion Diagnostics Development
    • 3.3.2 CDx Stakeholders
    • 3.3.3 Technologies Used in CDx
    • 3.3.4 Applications of CDx
    • 3.3.5 Regulatory Aspects of CDx

Chapter 4 Global Market for Companion Diagnostics by Product and Service

  • 4.1 Market Overview
  • 4.2 Market Share and Forecast
    • 4.2.1 Instruments
    • 4.2.2 Consumables
    • 4.2.3 Services

Chapter 5 Global Market for Companion Diagnostics by Type of Test

  • 5.1 Market Overview
  • 5.2 Market Share and Forecast
    • 5.2.1 LDT-CDx
    • 5.2.2 Commercial CDx

Chapter 6 Global Market for Companion Diagnostics by Technology

  • 6.1 Market Overview
  • 6.2 Market Share and Forecast
    • 6.2.1 Immunohistochemistry
    • 6.2.2 In Situ Hybridization
    • 6.2.3 Polymerase Chain Reaction
    • 6.2.4 Next-Generation Sequencing
    • 6.2.5 Genotyping
    • 6.2.6 Others
    • 6.2.7 Services

Chapter 7 Global Market for Companion Diagnostics by Application

  • 7.1 Market Overview
  • 7.2 Market Share and Forecast
    • 7.2.1 Cancer
    • 7.2.2 Market for the Application of CDx in Cancer by Type
    • 7.2.3 Neurologic Disorders
    • 7.2.4 Cardiovascular Disease
    • 7.2.5 Infectious Disease
    • 7.2.6 Other Diseases

Chapter 8 Global Market for Companion Diagnostics by Region

  • 8.1 North America
    • 8.1.1 U.S.
    • 8.1.2 Canada
  • 8.2 Europe
    • 8.2.1 Germany
    • 8.2.2 U.K.
    • 8.2.3 France
    • 8.2.4 Italy
    • 8.2.5 Rest of Europe
  • 8.3 Asia-Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 India
    • 8.3.4 Rest of Asia-Pacific
  • 8.4 Rest of the World

Chapter 9 Industry Structure

  • 9.1 Overview
  • 9.2 Stakeholders in Companion Diagnostics
  • 9.3 Driving Trends in Companion Diagnostics
  • 9.4 Business Models of Companion Diagnostics
  • 9.5 Grants and Funding in Companion Diagnostics
  • 9.6 Collaborations and Partnerships
  • 9.7 Mergers and Acquisitions
    • 9.7.1 Market Share Analysis
  • 9.8 Leading Market Players in Companion Diagnostics Market, by Technology
    • 9.8.1 Leading Market Players in IHC Market
    • 9.8.2 Leading Market Players in ISH Market
    • 9.8.3 Leading Market Players in PCR Market
    • 9.8.4 Leading Market Players in NGS Market
    • 9.8.5 Leading Market Players in Genotyping Market
    • 9.8.6 Leading Market Players in Others (Tropism, MRI) CDx Market

Chapter 10 Patent Review

  • 10.1 Introduction
  • 10.2 Patents on Companion Diagnostics Market
  • 10.3 Patent Analysis
    • 10.3.1 Patents by Year
    • 10.3.2 Patents by Top Applicant
    • 10.3.3 Patents by Top Owner
    • 10.3.4 Patents by Jurisdiction

Chapter 11 Clinical Trials Analysis

  • 11.1 Introduction
  • 11.2 Clinical Trials and CDx
  • 11.3 Clinical Trials Analysis
    • 11.3.1 Clinical Trials Analysis, by Type of Study
    • 11.3.2 Clinical Trials Analysis, by Status
    • 11.3.3 Clinical Trials Analysis, by Phase
    • 11.3.4 Clinical Trials Analysis, by Region
    • 11.3.5 Clinical Trials Analysis, by Application
    • 11.3.6 Companies with Companion Diagnostics in Clinical Trials

Chapter 12 Analysis of Market Opportunities

  • 12.1 Introduction
  • 12.2 Market Dynamics
    • 12.2.1 Strengths
    • 12.2.2 Challenges
    • 12.2.3 Opportunities
    • 12.2.4 Threats
  • 12.3 Impact of the COVID-19 Pandemic

Chapter 13 Company Profiles

  • ABBOTT
  • ADAPTIVE BIOTECHNOLOGIES CORP.
  • AGILENT TECHNOLOGIES INC.
  • AMOY DIAGNOSTICS CO., LTD.
  • ALMAC GROUP LTD.
  • ARUP LABORATORIES
  • AUTOGENOMICS INC. (ACQUIRED BY PRESCIENT MEDICINE)
  • BIOCARTIS
  • BIODESIX INC.
  • BIOFLUIDICA
  • BIOMERIEUX SA
  • BIO-TECHNE
  • CERBA RESEARCH
  • CIRCULOGENE
  • DANAHER
  • DIASORIN S.P.A.
  • EXACT SCIENCES CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • GUARDANT HEALTH INC.
  • HOLOGIC INC.
  • ICON PLC
  • ILLUMINA INC.
  • INVIVOSCRIBE INC.
  • MAZE THERAPEUTICS
  • MYRIAD GENETICS INC.
  • NEOGENOMICS LABORATORIES
  • QIAGEN
  • QUEST DIAGNOSTICS INC.
  • RESONANCE HEALTH LTD.
  • SIEMENS HEALTHINEERS AG
  • SPARTAN BIOSCIENCE INC.
  • SYSMEX CORP.
  • THERMO FISHER SCIENTIFIC INC.
  • TRIMGEN CORP.
  • VELA DIAGNOSTICS INC.

Chapter 14 Appendix: Acronyms